TICKERS: JNCE

AAA_Jounce Therapeutics ROTH RR
Research Report

Source: Streetwise Reports (11/9/21)

Psychedelic Drug Trials Accelerate as Decriminalization Spreads, Investment Expands
Source: McAlinden Research for Streetwise Reports (11/03/2021)

McAlinden Research Partners estimates it may be only a matter of time before psychedelics become part of a biotech boom.

Precision Medicine Co.'s ASM Treatment Drug Gaining Rapid Market Adoption
Source: Streetwise Reports (11/03/2021)

Wedbush Securities Inc. advised that global precision therapy company Blueprint Medicines Corp.'s therapeutic AYVAKIT is gaining traction in patients diagnosed with advanced systemic mastocytosis and gastrointestinal stromal tumors. Wedbush reiterated its Outperform rating for the company and raised its 12-month price target by $4.00 to $136.00 per share.

SLT Company's 'Cell Replacement in a Bottle' a Powerful Option in Treating Genetic Diseases
Source: Streetwise Reports (11/02/2021)

BTIG commented in a research report that Sigilon Therapeutics is developing a powerful and widely applicable "cell replacement in a bottle" as a potential functional cure for genetic diseases. BTIG advised it is initiating coverage on the company with a "Buy" rating and $14/share price target.

Shares of ANI Pharmaceuticals Inc. traded 50% higher after the company reported the U.S. FDA approved its Purified Cortrophin Gel for use in treating multiple sclerosis, rheumatoid arthritis and nephrotic syndrome.

Medpace Shares Rise 13% on Higher Q3 Earnings & Forward Outlook
Source: Streetwise Reports (10/26/2021)

Shares of Medpace Holdings Inc. climbed to a new 52-week high after the CRO, a provider of full-service clinical trial development services, reported financial results for Q3/21 that included a 28.3% increase in YoY revenue.